Amryt Pharma says it has made substantial progress since its admission to trading on AIM in April 2016. Photograph: iStock

Specialty drug group Amryt Pharma told shareholders Thursday that it had made “substantial progress” since listing on the London’s junior AIM market l(...)

Amryt is now primarily focused on going into clinical trials on a potential therapy for a treatment for a rare, debilitating hereditary skin disorder called epidermolysis bullosa

Amryt Pharmaceutical, the orphan drug development business that was subject to a reverse takeover by former oil and gas group Fastnet earlier this yea(...)

Amryt is now focused on clinical trials on a potential therapy for a rare skin disorder called epidermolysis bullosa

Amryt Pharmaceutical, the orphan drug development business that was subject to a reverse takeover by oil and gas group Fastnet, has updated the market(...)

Fastnet chairman Cathal Friel. Photograph: Fennell Photography

On April 18th, shareholders in Fastnet Oil & Gas – now known as Fastnet Equity – will be asked to give their approval to a reverse takeover by Amr(...)